Reporting owner · CIK 0002107187

Wilterding Mark

Visual SEC Form 4 history across 1 companies, 3 transactions and 1 filings.

CFOChief Financial OfficerRxSight, Inc.
Open-market mix
Filings1Form 4 records
Buying$00 purchases
Selling$54K1 sales
Net value−$54KBuys minus sells
Companies12 securities
Most recentSep 02, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Aug 261Sep 26

Net value flow

Buys minus sells

Aug 26
$0
Sep 26
−$54K

Transaction texture

Ownership and ticket size

Average P/S size$54K
Median P/S size$54K
Direct3
Indirect0
Sep 02, 2026sale

Filing-only signals

Deterministic matches in this insider's history

No filing-only signal badges matched this history.

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at RxSight, Inc. on Sep 02, 2026 valued at $54,044.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Associated companies

Visual map of known reporting history

TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
RXSTWilterding Mark
CFO
exercise20.4k$0M09/0308/31
RXSTWilterding Mark
CFO
sale7.76k-$5.40MS09/0309/02
RXSTWilterding Mark
CFO
exercise20.4kM09/0308/31

Wilterding Mark Insider Activity FAQ

SEC Form 4 context

Who is Wilterding Mark?

Wilterding Mark is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002107187.

Which companies has Wilterding Mark reported transactions for?

RxSight, Inc.

When was Wilterding Mark's latest insider buy?

No open-market insider purchase is available for this period.

When was Wilterding Mark's latest insider sale?

sale at RxSight, Inc. on Sep 02, 2026 valued at $54,044.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.